SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/25/2016 2:01:27 PM - Followers: 36 - Board type: Free - Posts Today: 0
Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with Ara-C) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at MD Anderson, Baylor and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with Ara-C and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore an FDA accelerated status after testing is complete on 19 additional patients.
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. 

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability o
f its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $13+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
BPTH is traded on the NASDAQ.

Here is the link to the recent peer paper prepared by their experts:

Analyst target price: Maxim $2, Zacks $3.50 and Rodman & Renshaw $5
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#2243   Daily trading volume from September to October is iloveu2 10/25/16 02:01:27 PM
#2242   Blair, I agree it is approved in a SJSTOCKSHARK 10/22/16 10:16:02 PM
#2241   Blairsoldman, BP1001 was approved through 6 phase I Snug9 10/22/16 01:32:53 PM
#2240   Blairsoldman, BP1001 is not approved for anything other wordlender 10/22/16 10:58:21 AM
#2239   You misunderstand my question. I was trying to blairsoldman 10/22/16 09:50:40 AM
#2238   Thanks Snug9 ! too simple 10/21/16 12:55:13 PM
#2237   Too Simple, you can see Insider Trading on Snug9 10/21/16 11:16:58 AM
#2236   Does anyone on this board follow insider trading too simple 10/21/16 10:37:13 AM
#2235   Blair, You have to near a test site SJSTOCKSHARK 10/20/16 08:18:08 PM
#2234   I understand that it is not approved for blairsoldman 10/20/16 10:47:57 AM
#2233   Blairs, The FDA has not approved the combination SJSTOCKSHARK 10/20/16 10:27:07 AM
#2232   My lack of medical background limits my comprehension blairsoldman 10/20/16 01:11:05 AM
#2231   Awesome! You guys are great, thanks! I just BPTH2008 10/18/16 12:51:38 PM
#2230   BP, The basic rules are as follows: SJSTOCKSHARK 10/18/16 11:44:40 AM
#2229   Thanks for your response! It's it something you BPTH2008 10/18/16 11:05:57 AM
#2228   Correction, my previous post should start with BP too simple 10/18/16 11:05:08 AM
#2227   No - It really is just a tax too simple 10/18/16 11:03:26 AM
#2226   My opinion is something is not right with vrock5656 10/18/16 07:39:34 AM
#2225   I can't argue with that statement. I have Gpheart2013 10/18/16 01:45:05 AM
#2224   This is going under $1 iloveu2 10/17/16 03:49:39 PM
#2223   TOO, GP and SJ... I'm sure I have nothing BPTH2008 10/17/16 12:59:28 PM
#2222   Gp- Agree with everything you said. But, I too simple 10/17/16 12:03:50 PM
#2221   We are getting close to a bottom IMHO. Gpheart2013 10/17/16 11:10:56 AM
#2220   SJ, I make more mistakes than anyone when Gpheart2013 10/17/16 10:39:45 AM
#2219   Word, Having a past experience of being cut SJSTOCKSHARK 10/16/16 01:48:37 PM
#2218   They are looking for patients that fit this description: wordlender 10/15/16 02:53:31 PM
#2217   There are obviously knowledgeable people contributing to this blairsoldman 10/14/16 03:07:06 PM
#2216   Thanks SJ ! Good info. too simple 10/11/16 06:57:28 PM
#2215   Sorry that post should have also been directed SJSTOCKSHARK 10/09/16 06:23:27 PM
#2214   Gp, I may hold off on the Roth SJSTOCKSHARK 10/07/16 03:27:55 PM
#2213   Looks like yet another opportunity to transfer to too simple 10/07/16 03:11:38 PM
#2212   Got a little mention in this research note here: wordlender 10/07/16 03:11:03 PM
#2211   An excellent question SJ. Maybe there will be Gpheart2013 10/07/16 11:50:40 AM
#2210   Why no news release on the CML safety study? SJSTOCKSHARK 10/07/16 11:20:35 AM
#2209   Details of the Ib/IIa CML study: enrollment Gpheart2013 10/05/16 02:47:44 PM
#2208   NEWS! Clinical shows a new phase Gpheart2013 10/05/16 02:27:45 PM
#2207   Barcharts analysis: short term 80%sell, medium term Gpheart2013 10/04/16 10:36:19 AM
#2206   GP, Can you post the updated opinion from SJSTOCKSHARK 10/03/16 06:34:15 PM
#2205   I do not think that the weak PPS Gpheart2013 09/29/16 03:38:33 PM
#2204   I am guessing that testing isn't going very vrock5656 09/29/16 01:34:00 PM
#2203   Not a very good signal ... just tanking vrock5656 09/26/16 11:34:01 AM
#2202   A buyout would be perfect. That could happen wordlender 09/23/16 05:33:52 PM
#2201   I am ready for a buyout. Check out SJSTOCKSHARK 09/21/16 03:07:51 PM
#2200   Still 13% of total shares owned by institutional investment. SJSTOCKSHARK 09/19/16 04:30:35 PM
#2199   Wordl. I wonder if those purchases related the SJSTOCKSHARK 09/19/16 01:54:27 PM
#2198   Thank you love. Gpheart2013 09/16/16 07:39:20 PM
#2197   It is because I sold all of mine iloveu2 09/16/16 01:51:03 PM
#2196   What is going on this morning? A big Gpheart2013 09/16/16 10:10:00 AM
#2195   With Biopath being in phase 2 efficacy trial wingshooterr 09/15/16 10:43:36 PM
#2194   Did you guys see this article? wordlender 09/15/16 04:03:55 PM